Agilent, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tycho Peterson from Jefferies maintained a Hold rating on the stock and has a $130.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tycho Peterson’s rating is based on a combination of factors surrounding Agilent’s recent product launch and market dynamics. Agilent’s introduction of the Altura Ultra Inert HPLC columns marks a significant development in their product line, being the first major column launch in a decade. This launch is expected to enhance the company’s consumables business by offering a product with superior performance attributes and a potential for premium pricing compared to existing offerings.
Despite the promising aspects of the new product, the Hold rating reflects a cautious stance due to broader market conditions and internal company challenges. The recent management changes and concerns over the company’s guidance for 2026, particularly regarding operating margin and growth projections, contribute to this cautious outlook. Additionally, while the new product could lead to pricing improvements and market share gains, these benefits may take time to materialize fully, warranting a Hold rating at this stage.
In another report released yesterday, Barclays also maintained a Hold rating on the stock with a $150.00 price target.